Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0889 • ACR Convergence 2025
Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis
Ziyuan He¹, Marla Glass¹, Pravina Venkatesan², Alexandra Ferrannini³, Marie Feser⁴, Christy Bennett¹, David Boyle⁵, Kristen Demoruelle⁶, Kristine Kuhn⁷, Fan Zhang⁸, Thomas Bumol⁹, Ananda Goldrath³, Peter Skene³, V. Michael Holers¹⁰, Xiaojun Li¹, Adam Savage¹, Gary Firestein¹¹, Kevin Deane¹², Troy Torgerson¹³ and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Seattle, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ⁸The University of Colorado, Aurora, CO, ⁹Allen Institute for Immunology, San Diego, CA, ¹⁰University of Colorado, Denver, CO, ¹¹University of California, San Diego, San Diego, CA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Prior to the onset of clinically apparent inflammatory arthritis (IA)/synovitis (clinical RA), ACPA+ ‘at-risk’ individuals (ARI) show alterations in the abundance of effector T…
Abstract Number: 0800 • ACR Convergence 2025
Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production
Jing Jing Li¹, Sucai Liu², Brenda Seymour³, Brendan Allen², Le Yiphyo², Cassandra Levens¹ and Kristine Kuhn⁴, ¹Rheumatology, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado School of Medicine, Denver, CO, ⁴²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: One of the most substantial impacts of microbe-host interactions at the intestinal mucosa is the development of type 17 immunity. A Th17 signature has…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0481 • ACR Convergence 2025
Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
Chandrashekara MN¹, AASTHA KHULLAR², Bidyalaxmi Leishangthem³, Shankar Naidu⁴, Varun Dhir⁵ and Sanjay Jain⁴, ¹PGIMER, Chandigarh, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, CHANDIGARH, Chandigarh, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴Post graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, Chandigarh, India, ⁵PGIMER, CHD, INDIA, CHANDIGARH, Chandigarh, India
Background/Purpose: Methotrexate (MTX) polyglutamates (MTX-PGs), the intracellular active forms of MTX, are hypothesized to reflect cumulative exposure and potentially predict therapeutic efficacy in rheumatoid arthritis…
Abstract Number: 0465 • ACR Convergence 2025
Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Suchita Nety¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Qianru Zhang¹, Nancy Shadick⁵, Michael Weinblatt⁶, Liya Sisay Getachew⁷, Gregory McDermott⁸ and Jeffrey Sparks⁷, ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women's Hospital, Brookline, MA
Background/Purpose: RA-associated lung diseases (RA-LD) such as RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR) are more common in men, but risk rises with…
Abstract Number: 0448 • ACR Convergence 2025
Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Ioannis Koulas¹, Nikolaos Tsaftaridis², Marios Gkionis³, Giancarlo Paternoster⁴, Sunit Jariwala⁵ and Konstantinos Loupasakis⁶, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²The Feinstein Institutes for Medical Research, Manhasset, ³NTNU, Department of Engineering Cybernetics, Trondheim, Norway, ⁴Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁶Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Although Large Language Models (LLMs) have been successfully used in the analysis of data from Electronic Health Records (EHRs), their implementation in the field…
Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Sangeeta Kumari¹, Eric meldrum¹, Josephine Stein¹, Tirza Bruurmijn¹, Robin de Jong², Katerina Pardali¹, Maarten Kraan¹, Renato Chirivi¹, Rogier Thurlings³ and Michael Nurmohamed², ¹Citryll BV, Oss, Netherlands, ²Reade, Amsterdam, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…
Abstract Number: 0221 • ACR Convergence 2025
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
Grant Cannon¹, Beth Wallace², Deana Lazaro³, Pascale Schwab⁴, Paul Monach⁵, Ankoor Shah⁶, Gail Kerr⁷, Andreas Reimold⁸, Joshua Baker⁹, Gary Kunkel¹⁰, Katherine Wysham¹¹, Liron Caplan¹², John Richards¹³, Aleksander Lenert¹⁴, Andrew Jones¹⁵, Ted Mikuls¹⁶, Maria I. ("Maio") Danila¹⁷, Bryant England¹⁶, Brian Sauer¹⁸, Jorge Rojas¹⁹ and Isaac Smith²⁰, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³VA New York Harbor Healthcare system, Short Hills, NJ, ⁴VA Portland and Oregon Health & Science University, Portland, OR, ⁵VA Boston Healthcare System, Boston, MA, ⁶Duke University, Durham, NC, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ¹²Rocky Mountain Regional VAMC, Aurora, CO, ¹³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁴University of Iowa, Iowa City, IA, ¹⁵VA Saint Louis and Washington University, Saint Louis, ¹⁶University of Nebraska Medical Center, Omaha, NE, ¹⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁹VA Puget Sound Health Care System, Seattle, WA, ²⁰Duke University Hospital, Durham, NC
Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…
Abstract Number: 0166 • ACR Convergence 2025
Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
Tim Filla¹, Gamal Chehab¹, Jutta Richter², Jörg Distler³ and Oliver Sander¹, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ²Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, ³University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Environmental influences affect the human body throughout life, from conception to old age. The influence of air pollution and fine dust particles on systemic…
Abstract Number: 0085 • ACR Convergence 2025
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Kensuke Suga¹, Amara Seng², Changfu Yao³, Tanyalak Parimon³, Youn Jung Choi², Justyna Fert-Bober⁴, Barry Stripp³, Jon Giles⁵, Peter Chen³ and Nunzio Bottini⁶, ¹Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…
Abstract Number: 0067 • ACR Convergence 2025
Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
Amara Seng¹, Kensuke Suga², Diana Tran³, Anvita Singaraju⁴, Tanyalak Parimon⁵, Youn Jung Choi⁶, Justyna Fert-Bober⁷, Jon Giles⁸, Peter Chen⁵ and Nunzio Bottini⁹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ³Cedars Sinai Medical Center, La Cañada Flintridge, CA, ⁴Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, ⁵Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cedars Sinai Medical Center, Los Angeles, CA, ⁹Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Symptomatic rheumatoid arthritis-related interstitial lung disease (RA-ILD) is prevalent in about 10% of patients with RA and confers a higher mortality compared with RA…
Abstract Number: 0022 • ACR Convergence 2025
Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
Austin Wheeler¹, Thomas Riley², Riku Takei³, Joshua Baker², Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Ted Mikuls¹, Tony Merriman¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Interstitial lung disease (ILD) is clinically present in ~10% of individuals with RA. There is recognized overlap between RA-ILD and idiopathic pulmonary fibrosis (IPF)…
Abstract Number: 2640 • ACR Convergence 2025
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Sho Fukui¹, Hilde Ørbo², Sara Tedeschi¹, Hongshu Guan³, Leslie Harrold⁴, Heather Litman⁵ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Diakonhjemmet Hospital, Oslo, Norway, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴CorEvitas, Northborough, MA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Kidney dysfunction is common in patients with rheumatoid arthritis (RA). However, there has been limited and conflicting evidence on the effectiveness of biologic and…
Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 2273 • ACR Convergence 2025
Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
FRANK BUTTGEREIT¹, Andrew Ostor², Philip Conaghan³, Ana Romero⁴, Ivan Lagunes⁵, Andrew Garrison⁶, Tianming Gao⁷ and Suzan Attar⁸, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Australian National University, Canberra, Australia, ³University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Barcelona, Spain, ⁵Abbvie Inc, North Chicago, IL, ⁶AbbVie, USA, North Chicago, IL, ⁷AbbVie, North Chicago, IL, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia

Background/Purpose: Glucocorticoids (GCs) are fast-acting drugs used to support csDMARD therapy for RA, but should be used sparingly and for short periods.1 Upadacitinib, an oral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].